Literature DB >> 30610067

Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial.

Benjamin Burggraaf1, Deborah F van Breukelen-van der Stoep2, Marijke A de Vries3, Boudewijn Klop3, Anho H Liem4, Gert-Jan M van de Geijn5, Noelle van der Meulen3, Erwin Birnie6, Ellen M van der Zwan5, Jende van Zeben2, Manuel Castro Cabezas3.   

Abstract

BACKGROUND: Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular disease (CVD). No long-term intervention trials on CVD risk factors have been published, and a debate on the efficacy of controlling traditional risk factors in RA is ongoing. We aimed to evaluate a treat-to-target approach versus usual care regarding traditional CVD risk factors in patients with RA.
METHODS: In this open-label, randomised controlled trial, patients with RA aged <70 years without prior CVD or diabetes mellitus were randomised 1:1 to either a treat-to-target approach or usual care of traditional CVD risk factors. The primary outcome was defined as change in carotid intima media thickness (cIMT) over 5 years, and the secondary outcome was a composite of first occurrence of fatal and non-fatal cardiovascular events.
RESULTS: A total of 320 patients (mean age 52.4 years; 69.7% female) with RA underwent randomisation and 219 patients (68.4%) completed 5 years of follow-up. The mean cIMT progression was significantly reduced in the treat-to-target group compared with usual care (0.023 [95% CI 0.011 to 0.036] mm vs 0.045 [95% CI 0.030 to 0.059] mm; p=0.028). Cardiovascular events occurred in 2 (1.3%) of the patients in the treat-to-target group vs 7 (4.7%) in those receiving usual care (p=0.048 by log-rank test).
CONCLUSION: This study provides evidence on the benefit of a treat-to-target approach of traditional CVD risk factors for primary prevention in patients with well-treated RA. TRIAL REGISTRATION NUMBER: NTR3873. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  atherosclerosis; cardiovascular risk; intervention; rheumatoid arthritis

Mesh:

Substances:

Year:  2019        PMID: 30610067     DOI: 10.1136/annrheumdis-2018-214075

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.

Authors:  Peter Willeit; Lena Tschiderer; Michael J Sweeting; Simon G Thompson; Matthias W Lorenz; Elias Allara; Kathrin Reuber; Lisa Seekircher; Lu Gao; Ximing Liao; Eva Lonn; Hertzel C Gerstein; Salim Yusuf; Frank P Brouwers; Folkert W Asselbergs; Wiek van Gilst; Sigmund A Anderssen; Diederick E Grobbee; John J P Kastelein; Frank L J Visseren; George Ntaios; Apostolos I Hatzitolios; Christos Savopoulos; Pythia T Nieuwkerk; Erik Stroes; Matthew Walters; Peter Higgins; Jesse Dawson; Paolo Gresele; Giuseppe Guglielmini; Rino Migliacci; Marat Ezhov; Maya Safarova; Tatyana Balakhonova; Eiichi Sato; Mayuko Amaha; Tsukasa Nakamura; Kostas Kapellas; Lisa M Jamieson; Michael Skilton; James A Blumenthal; Alan Hinderliter; Andrew Sherwood; Patrick J Smith; Michiel A van Agtmael; Peter Reiss; Marit G A van Vonderen; Stefan Kiechl; Gerhard Klingenschmid; Matthias Sitzer; Coen D A Stehouwer; Heiko Uthoff; Zhi-Yong Zou; Ana R Cunha; Mario F Neves; Miles D Witham; Hyun-Woong Park; Moo-Sik Lee; Jang-Ho Bae; Enrique Bernal; Kristian Wachtell; Sverre E Kjeldsen; Michael H Olsen; David Preiss; Naveed Sattar; Edith Beishuizen; Menno V Huisman; Mark A Espeland; Caroline Schmidt; Stefan Agewall; Ercan Ok; Gülay Aşçi; Eric de Groot; Muriel P C Grooteman; Peter J Blankestijn; Michiel L Bots
Journal:  Circulation       Date:  2020-06-17       Impact factor: 29.690

2.  Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis.

Authors:  Alessandro Giollo; Giovanni Cioffi; Federica Ognibeni; Giovanni Orsolini; Andrea Dalbeni; Riccardo Bixio; Giovanni Adami; Angelo Fassio; Luca Idolazzi; Davide Gatti; Maurizio Rossini; Ombretta Viapiana
Journal:  Arthritis Res Ther       Date:  2021-06-03       Impact factor: 5.156

3.  Improved Incidence of Cardiovascular Disease in Patients With Incident Rheumatoid Arthritis in the 2000s: A Population-based Cohort Study.

Authors:  Elena Myasoedova; John M Davis; Veronique L Roger; Sara J Achenbach; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2021-02-15       Impact factor: 5.346

4.  Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.

Authors:  Piero Ruscitti; Paola Cipriani; Vasiliki Liakouli; Daniela Iacono; Ilenia Pantano; Domenico Paolo Emanuele Margiotta; Luca Navarini; Giulia Maria Destro Castaniti; Nicola Maruotti; Gerardo Di Scala; Licia Picciariello; Francesco Caso; Sara Bongiovanni; Rosa Daniela Grembiale; Fabiola Atzeni; Raffaele Scarpa; Federico Perosa; Giacomo Emmi; Francesco Paolo Cantatore; Giuliana Guggino; Antonella Afeltra; Francesco Ciccia; Roberto Giacomelli
Journal:  Arthritis Res Ther       Date:  2019-09-03       Impact factor: 5.156

5.  Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis.

Authors:  Shubhasree Banerjee; Michael D George; Sukhraj Singh; Jennifer Tchervenkov; Amber Van Heusen; Mohamed Tageldin; Mark Riley; Muhammad Saad Shaukat; Nicholas Demenagas; Kevin Le; Tiffany Oliveira; Sooyeon Kwon; Paul Feustel; Joel M Kremer
Journal:  ACR Open Rheumatol       Date:  2020-04-20

Review 6.  Clinical application of mesenchymal stem cells in rheumatic diseases.

Authors:  Yajing Wang; Dan Ma; Zewen Wu; Baoqi Yang; Rong Li; Xingxing Zhao; Helin Yang; Liyun Zhang
Journal:  Stem Cell Res Ther       Date:  2021-11-09       Impact factor: 6.832

Review 7.  Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases.

Authors:  Saade Abdalkareem Jasim; Alexei Valerievich Yumashev; Walid Kamal Abdelbasset; Ria Margiana; Alexander Markov; Wanich Suksatan; Benjamin Pineda; Lakshmi Thangavelu; Seyed Hossein Ahmadi
Journal:  Stem Cell Res Ther       Date:  2022-03-07       Impact factor: 6.832

Review 8.  Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes.

Authors:  Peter C Taylor; Marco Matucci Cerinic; Rieke Alten; Jérôme Avouac; Rene Westhovens
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-08-16       Impact factor: 3.625

9.  Association between Carotid Intima-Media Thickness and the Use of Biological or Small Molecule Therapies in Patients with Rheumatoid Arthritis.

Authors:  Marta Rojas-Giménez; Clementina López-Medina; Jerusalem Calvo-Gutiérrez; María Ángeles Puche-Larrubia; Ignacio Gómez-García; Pedro Seguí-Azpilcueta; María Del Carmen Ábalos-Aguilera; Desirée Ruíz; Eduardo Collantes-Estévez; Alejandro Escudero-Contreras
Journal:  Diagnostics (Basel)       Date:  2021-12-28

10.  Postprandial Hyperlipidemia: Association with Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis.

Authors:  Natalia Mena-Vázquez; Rocío Redondo-Rodríguez; José Rioja; Francisco Gabriel Jimenez-Nuñez; Sara Manrique-Arija; Jose Manuel Lisbona-Montañez; Laura Cano-García; Marta Rojas-Gimenez; Inmaculada Ureña; Pedro Valdivielso; Antonio Fernández-Nebro
Journal:  Biomedicines       Date:  2022-01-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.